Hamburg (ots) - Mehr als drei Viertel (77 Prozent) der Frauen über 50 Jahre in Deutschland kennen den Risikofaktor höheres ...

AstraZeneca and Honeywell are developing MDIs that will use a new propellant called HFO-1234ze, which, according to the company, has 99.9% less Global Warming Potential (GWP) than existing ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

Mindpeak, ein führender Anbieter von KI-gestützten Lösungen für die digitale Pathologie, gibt eine neue Partnerschaft mit dem weltweit agierenden biopharmazeutischen Unternehmen AstraZeneca ...

AstraZeneca’s (AZN) Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with resectable non-small cell lung cancer, NSCLC, at high ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £142.00. The company’s shares opened today at p11 ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...

EsoBiotec will become a wholly owned subsidiary of AstraZeneca, with operations in Belgium. New platform allows quicker cancer treatment delivery. In a market dominated by tariff tensions ...

(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) announced Monday that it has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company, for a total ...